Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,401-1,450 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__87_A3,7 | Lung | Primary cancer | 3,205 | Tumor/Malignant | 73.8% | 0.98 | 0.10 |
| NSCLC_38242124__IMC__87_A3,8 | Lung | Primary cancer | 3,915 | Tumor/Malignant | 57.4% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__87_A3,9 | Lung | Primary cancer | 4,014 | Tumor/Malignant | 64.8% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__87_A4,1 | Lung | Primary cancer | 3,759 | Tumor/Malignant | 40.6% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__87_A4,10 | Lung | Primary cancer | 3,820 | Other | 35.8% | 0.39 | 1.04 |
| NSCLC_38242124__IMC__87_A4,12 | Lung | Primary cancer | 3,390 | Tumor/Malignant | 64.5% | 0.98 | 0.10 |
| NSCLC_38242124__IMC__87_A4,13 | Lung | Primary cancer | 2,653 | Stromal | 36.6% | 0.46 | 0.90 |
| NSCLC_38242124__IMC__87_A4,14 | Lung | Primary cancer | 3,605 | Tumor/Malignant | 80.9% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__87_A4,15 | Lung | Primary cancer | 4,673 | Tumor/Malignant | 44.6% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__87_A4,16 | Lung | Primary cancer | 3,849 | Tumor/Malignant | 70.2% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__87_A4,17 | Lung | Primary cancer | 3,131 | Tumor/Malignant | 37.6% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__87_A4,2 | Lung | Primary cancer | 4,091 | Stromal | 26.7% | 0.64 | 0.67 |
| NSCLC_38242124__IMC__87_A4,3 | Lung | Primary cancer | 3,174 | Stromal | 34.5% | 0.52 | 0.91 |
| NSCLC_38242124__IMC__87_A4,4 | Lung | Primary cancer | 2,901 | Tumor/Malignant | 58.4% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_A4,5 | Lung | Primary cancer | 2,110 | Stromal | 35.9% | 0.32 | 1.04 |
| NSCLC_38242124__IMC__87_A4,6 | Lung | Primary cancer | 2,883 | Tumor/Malignant | 38.3% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__87_A4,7 | Lung | Primary cancer | 3,672 | Tumor/Malignant | 37.3% | 0.69 | 0.65 |
| NSCLC_38242124__IMC__87_A4,8 | Lung | Primary cancer | 3,946 | Immune | 34.2% | 0.92 | 0.21 |
| NSCLC_38242124__IMC__87_A4,9 | Lung | Primary cancer | 2,785 | Tumor/Malignant | 60.3% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__87_A5,1 | Lung | Primary cancer | 3,432 | Immune | 35.5% | 0.87 | 0.40 |
| NSCLC_38242124__IMC__87_A5,10 | Lung | Primary cancer | 2,915 | Immune | 29.2% | 0.48 | 0.91 |
| NSCLC_38242124__IMC__87_A5,11 | Lung | Primary cancer | 3,801 | Tumor/Malignant | 65.4% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__87_A5,12 | Lung | Primary cancer | 2,769 | Tumor/Malignant | 46.7% | 0.53 | 0.62 |
| NSCLC_38242124__IMC__87_A5,13 | Lung | Primary cancer | 2,631 | Tumor/Malignant | 50.4% | 0.85 | 0.35 |
| NSCLC_38242124__IMC__87_A5,14 | Lung | Primary cancer | 4,056 | Tumor/Malignant | 54.2% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__87_A5,15 | Lung | Primary cancer | 3,163 | Tumor/Malignant | 75.3% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__87_A5,17 | Lung | Primary cancer | 2,997 | Tumor/Malignant | 66.8% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__87_A5,2 | Lung | Primary cancer | 3,481 | Tumor/Malignant | 36.7% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__87_A5,3 | Lung | Primary cancer | 4,725 | Tumor/Malignant | 73.7% | 0.96 | 0.11 |
| NSCLC_38242124__IMC__87_A5,4 | Lung | Primary cancer | 4,541 | Tumor/Malignant | 38.1% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__87_A5,5 | Lung | Primary cancer | 3,517 | Stromal | 32.7% | 0.90 | 0.32 |
| NSCLC_38242124__IMC__87_A5,6 | Lung | Primary cancer | 1,553 | Immune | 50.9% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__87_A5,7 | Lung | Primary cancer | 3,762 | Immune | 31.5% | 0.53 | 0.82 |
| NSCLC_38242124__IMC__87_A5,8 | Lung | Primary cancer | 2,195 | Tumor/Malignant | 44.0% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__87_A5,9 | Lung | Primary cancer | 3,263 | Tumor/Malignant | 78.9% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_A6,1 | Lung | Primary cancer | 2,984 | Tumor/Malignant | 30.0% | 0.95 | 0.20 |
| NSCLC_38242124__IMC__87_A6,10 | Lung | Primary cancer | 5,254 | Immune | 97.8% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__87_A6,11 | Lung | Primary cancer | 2,164 | Tumor/Malignant | 49.3% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__87_A6,12 | Lung | Primary cancer | 2,132 | Stromal | 45.0% | 0.89 | 0.29 |
| NSCLC_38242124__IMC__87_A6,13 | Lung | Primary cancer | 763 | Stromal | 48.1% | 0.29 | 1.05 |
| NSCLC_38242124__IMC__87_A6,14 | Lung | Primary cancer | 3,661 | Tumor/Malignant | 67.1% | 0.98 | 0.11 |
| NSCLC_38242124__IMC__87_A6,15 | Lung | Primary cancer | 2,857 | Tumor/Malignant | 67.9% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__87_A6,17 | Lung | Primary cancer | 2,087 | Tumor/Malignant | 39.7% | 0.73 | 0.63 |
| NSCLC_38242124__IMC__87_A6,2 | Lung | Primary cancer | 3,826 | Stromal | 38.7% | 0.38 | 1.02 |
| NSCLC_38242124__IMC__87_A6,3 | Lung | Primary cancer | 790 | Stromal | 34.7% | 0.49 | 0.83 |
| NSCLC_38242124__IMC__87_A6,4 | Lung | Primary cancer | 3,966 | Tumor/Malignant | 47.3% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__87_A6,5 | Lung | Primary cancer | 3,071 | Stromal | 27.2% | 0.87 | 0.39 |
| NSCLC_38242124__IMC__87_A6,6 | Lung | Primary cancer | 951 | Stromal | 37.7% | 0.87 | 0.37 |
| NSCLC_38242124__IMC__87_A6,7 | Lung | Primary cancer | 2,781 | Immune | 30.0% | 0.87 | 0.36 |
| NSCLC_38242124__IMC__87_A6,8 | Lung | Primary cancer | 2,315 | Stromal | 32.7% | 0.76 | 0.62 |